News

TSO3 ’s Chief Science Officer to moderate Educational Panel at the IAHCSMM Annual Congress

Thursday, April 26, 2018

Quebec City, Canada and Myrtle Beach, United States, April 26, 2018 – TSO3 Inc. (TSX: TOS), (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company’s Chief Science Officer, Brad Catalone, will moderate an educational session during the 60th annual International Association of Healthcare Central Service Material Management (IAHCSMM) Congress, being held in Phoenix, Arizona – April 29 to May 2, 2018.

Read more

News

TSO3 Details Results of Prion Inactivation Studies

Thursday, April 26, 2018

Quebec City, Canada and Myrtle Beach, United States, April 26, 2018 – TSO3 Inc. (TSX: TOS), (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that an independent laboratory has completed studies demonstrating the efficacy of the STERIZONE® VP4 Sterilizer for inactivation of prions.

Read more

News

TSO3 Appoints Dr. Douglas Dieter to its Board of Directors

Monday, April 2, 2018

Quebec City, Canada and Myrtle Beach, United States, April 2, 2018 – TSO3 Inc. (TSX: TOS), (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has appointed Dr. Doug Dieter to its board of directors.

Read more

News

TSO3 Reports Fourth Quarter and Full Year 2017 Results

Tuesday, March 20, 2018

Quebec City, Canada and Myrtle Beach, United States, – March 20, 2018 – TSO3 Inc. (TSX: TOS) (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, reported financial results for the fourth quarter and year ended December 31, 2017.

Read more

News

TSO3 Submits Response to US Regulators in Support of Terminal Sterilization of Duodenoscopes

Monday, March 19, 2018

Quebec City, Canada and Myrtle Beach, United States, March 19, 2018 – TSO3 Inc. (TSX: TOS), (“TSO3” or the “Company”), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has provided its final Additional Information (AI) response to US Regulators in support of extending the claims of the Company’s STERIZONE® VP4 Sterilizer to include the terminal sterilization of duodenoscopes.

Read more